BioNTech SE at JPMorgan Healthcare Conference Transcript
Great. Good morning, everyone. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan, and we're delighted to be continuing the conference today with BioNTech. (Operator Instructions) So with that, let me turn it over to BioNTech CEO, Ugur Sahin, for the presentation.
Yes. Thank you for joining us today, and thank you for the JPM team for inviting us here. It's a pleasure to present here. So first of all, the usual forward-looking statements and some safety information about our vaccine. I would like to start, again, as always, with our vision. Our vision is to harness the power of the immune system to fight human diseases. And in the last 3 years, we were encountered with a terrible pandemic, and we were able to respond to this pandemic with a life-saving vaccine. We were in this privileged situation based on 20 years of research based on preparedness and it shows what technology, science and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |